Clinical Trial Search

Primary: Number of Participants With Treatment Response Based on Total PANSS Scale Score — 195 Participants

Primary: Major Symptom Score (MSS) Assessed by the Investigator — 2.38; 3.41 units on a scale

Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants

Primary: Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of…

Primary: Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) — 0.049; -0.022 liters — p=<0.0001

Primary: The Primary Endpoint Will be in Hospital Major Bleed as Defined by the Study Protocol, Assessed at Three Time Points: After Study Drug Administration, But Prior to…

Primary: Total Pain Relief Based on Numerical Rating Scale (NRS) Score — 17.7; 12.4; 13.3 Units on a scale — p=<0.0001

Primary: Amount ($) Earned for Targeted Prosocial and Healthy Behaviors — 16.21 $ Vouchers

Primary: Percentage Surface Microhardness Recovery (%SMHR) Dose Response Relationship — 30.89; 28.71; 25.28; 21.03 %SMHR — p=<0.0001

Primary: Change in Glycosylated Hemoglobin (HbA1c) — 8.13; 8.19; -1.00; -1.05 percentage — p=0.4602

Primary: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 12 Weeks. — 0.134; 0.293; 0.262 Liter — p=0.0005

Primary: Quality of Life, Physical Health Composite — 46.8; 46.4; 47.2 units on a scale

Primary: Clearance of Sugammadex by Dialysis as Measured by the Reduction Ratio (RR) — 0.687; 0.566; 0.516; 0.532 Reduction Ratio

Primary: Change in Glcosylated Hemoglobin (HbA1c) — 8.59; 8.65; -0.98; -0.88 percentage — p=0.2534

Primary: Mean Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at Week 12 — 0.196; 0.332; 0.368 Liters…